Will Johnson & Johnson Be a Trillion-Dollar Stock by 2032?

Johnson & Johnson (NYSE: JNJ) is one of the largest healthcare companies in the world. However, the drugmaker is currently going through a transition. The company is spinning off its consumer health division, which is home to popular over-the-counter brands such as Neutrogena, Aveeno, Tylenol, and more. This ongoing planned separation should be complete by the end of the year.

The split will affect Johnson & Johnson's stock price and market cap -- which is $432.8 billion as of this writing -- but the company will remain one of the most prominent healthcare players in the world. And given its leadership in the pharmaceutical and medical devices (medtech) industries, Johnson & Johnson still has plenty of room to grow. But can the company join the exclusive group of trillion-dollar corporations within 10 years?